# To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

> **NCT05140863** · PHASE3 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 372 (actual)

## Conditions studied

- Postherpetic Neuralgia

## Interventions

- **DRUG:** HSK16149 20mg BID
- **DRUG:** HSK16149 40mg BID
- **DRUG:** Placebo BID

## Key facts

- **NCT ID:** NCT05140863
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2022-12-22
- **Final completion:** 2023-01-05
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140863, "To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05140863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*